Soricimed Biopharma Inc.

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Soricimed Biopharma Inc. is a privately-held, clinical stage company focused on the development of first-in-class cancer treatments from its targeting peptide platform.

The Company’s lead drug candidate, SOR-C13, is a first-in-class selective inhibitor of TRPV6 - a calcium channel over-expressed by solid tumour cancers. TRPV6 expression level is correlated with poor outcomes for solid tumour cancer patients.

An Investigator Initiated Phase 1b late-stage cancer trial is currently underway at the University of Texas MD Anderson Cancer Center.

The FDA has granted orphan-drug designation to SOR-C13 for pancreatic cancer and ovarian cancer.

Soricimed recently launched a collaboration to develop a targeted peptide receptor radiotherapy (PRRT).

Finally, Soricimed has successfully constructed peptide-drug conjugates (PDCs) that specifically target cancer cells by way of binding to TRPV6.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Prince Edward Island
Company HQ Country:
Canada
Year Founded:
2005
Main Therapeutic Focus:
Lead Product in Development:
SOR-C13
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3+
Speaker
photo
CEO
Soricimed Biopharma Inc.